Skip to content

Clinical efficacy study of repetitive transcranial magnetic stimulation in treating gait disorders of Parkinson's disease based on wearable device analysis

Clinical efficacy study of repetitive transcranial magnetic stimulation in treating gait disorders of Parkinson's disease based on wearable device analysis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118477
Enrollment
Unknown
Registered
2026-02-06
Start date
2026-01-20
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Group M1:Repetitive transcranial magnetic stimulation treatment in area M1
Group PPC:Repetitive transcranial magnetic stimulation treatment in area PPC
Group M1+PPC:Repetitive transcranial magnetic stimulation treatment in area M1+PPC
The sham stimulation group:Fake stimulus action

Sponsors

The First Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. It meets the revised diagnostic criteria for Parkinson's disease (PD) by the International Parkinson and Movement Disorder Society (MDS) in 2015, and is at Hoehn-Yahr (H-Y) stage 2-3. 2. There is a clear gait disorder, with a score of >= 2 points in the "gait" item of the Unified Parkinson's Disease Rating Scale (UPDRS) III, or a score of >= 3 points in the Simple Gait Analysis Scale (SGA). 3. The age ranges from 40 to 85 years old, with no gender restrictions, and is able to cooperate with rTMS treatment and data collection by wearable devices. 4. Voluntary signing of the informed consent form and approval by the hospital's ethics committee.

Exclusion criteria

Exclusion criteria: 1. There are contraindications for rTMS treatment, such as intracranial metallic implants (except for cochlear implants), a history of epilepsy, severe brain trauma or sequelae of stroke, and mental disorders (such as a depression score of =17 on the depression scale). 2. Patients with severe cardiopulmonary dysfunction, liver or kidney failure, or systemic diseases such as malignant tumors cannot tolerate the treatment and follow-up. 3. Gait disorders are caused by other diseases (such as lumbar spinal stenosis, arthritis, cerebellar lesions), rather than being caused by PD itself. 4. They cannot wear wearable devices (such as skin allergies, severe limitations in limb movement) or have cognitive impairments (Montreal Cognitive Assessment Scale MoCA score

Design outcomes

Primary

MeasureTime frame
Gait;

Countries

China

Contacts

Public ContactYang Xinglong

The First Affiliated Hospital of Kunming Medical University

yxldoc11@163.com+86 159 6941 0018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026